A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

The health sector witnesses significant developments with Eli Lilly's promising weight-loss drug trials and a $40 million ...

Chile is heading into a high-stakes presidential runoff defined by sharply contrasting visions of the country’s recent past ...

Days of torrential rain in Washington state has caused historic floods, stranding families on rooftops and washing over ...

A federal judge ordered the release of Kilmar Abrego Garcia, the man who was wrongfully deported, returned to the U.S. and is now facing criminal charges. This marks a major legal victory for Abrego ...

Elon Musk voiced a negative retrospective view of his grand government reform project, the Department of Government ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S. Starting Monday, the lowest dose vial will cost ...

Eli Lilly and Novo Nordisk are collaborating with Waltz Health to launch direct-to-employer access for obesity management medications. Waltz Health gave no information on the prices of GLP-1 drugs ...

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...

Eli Lilly has surged 47% since my last article, exceeding my previous $800 price target and reaching all-time highs near $1,030. LLY's leadership in the obesity treatment market continues to drive top ...

Eli Lilly (LLY) remains a core holding at 7% of NAV, but I have trimmed my position by 50% after a 38.8% price return since purchasing earlier in 2025. I have taken the proceeds and increased my MP ...